# About Thymosin Alpha-1 Store: An Independent Research Digest

> About this Thymosin Alpha-1 digest — an independent editorial project summarizing the peer-reviewed literature on the thymic immunomodulator. Not a clinic, not a vendor.

An independent editorial reading of the published literature — what it establishes, and what it does not.

## What this project is

Thymosin Alpha-1 Store is an independent editorial project that publishes summaries of the peer-reviewed research literature on Thymosin Alpha-1 (the synthetic drug form is thymalfasin). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The word 'store' in the domain is editorial framing — a position this publisher occupies relative to the literature, a place where the research is gathered and ordered — not a claim that the site sells anything. No product is offered here, no price is quoted, and no purchase is possible.

## How we read the evidence

Our method is to attribute every quantitative claim to its source and to keep the caveats in view. For a compound whose trial base is heterogeneous and often single-region, that means stating each finding as study-attributed rather than as settled fact, and surfacing the inconvenient results as prominently as the favourable ones — the phase-3 TESTS sepsis trial, for instance, was null, and we say so on every relevant page. We rely on PubMed-indexed primary literature, systematic reviews, and meta-analyses, and we do not cite what we cannot link.

## What we are careful about

We are precise about identity, because this peptide is constantly confused with others: Thymosin Alpha-1 is a different molecule from thymosin beta-4 (TB-500), thymulin, thymopentin, thymalin, and its own precursor prothymosin alpha. We frame it accurately as an immunomodulator, not an anabolic or performance compound. We note plainly that it is not approved for marketing in the United States. And we render no human dosing — doses appear only as study parameters, attributed to a population and a route.

---

A mechanism-first reading of the Thymosin Alpha-1 literature — each finding resolved to its own study like a band on a blot, the null sepsis trial kept in plain view; no clinic behind the bench, and nothing here dosed, prescribed, or sold.